Back to Search Start Over

[Experience of clinical use of fluvoxamine for the treatment of comorbid depression in childhood and adolescence].

Authors :
Goryunov AV
Golubeva NI
Shushpanova OV
Source :
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2023; Vol. 123 (11. Vyp. 2), pp. 14-21.
Publication Year :
2023

Abstract

Objective: To identify the frequency of administration of fluvoxamine, to determine the main targets of the drug and the expediency of its use in depression of various genesis in children and adolescents.<br />Material and Methods: To assess the frequency of prescribing fluvoxamine, 195 medical histories of patients who were inpatients in the children's department of the Mental Health Research Center in 2023 were analyzed. To assess the dynamics of depression during treatment with fluvoxamine, a clinical group was formed of 12 patients aged 10 to 15 years (age 13.1±3.6 years) who received fluvoxamine for the treatment of depression with comorbid obsessive-compulsive and anxiety-phobic disorders. Clinical and psychopathological, psychometric (Hamilton Depression Rating Scale - HDRS) and statistical research methods were used.<br />Results: In total, in 2023, fluvoxamine was received by 20% ( n =37) of all inpatient patients of child age (from 7 to 16 years). All patients received combination therapy. The therapeutic targets were comorbid depressive, obsessive-compulsive and anxiety symptoms developing in the structure of nosologically heterogeneous states, with the dominance of schizophrenic spectrum disorders. Against the background of the use of the drug fluvoxamine for 4 weeks in the clinical group, there was a significant reduction in depressive symptoms on the HDRS. Adverse events during complex therapy were observed in 20% of patients, but were not severe, did not require discontinuation of therapy and were unreliably associated with the use of fluvoxamine.<br />Conclusion: The use of the fluvoxamine provides reduction of depressive symptoms within the framework of various nosologies, and is characterized by sufficient safety. The variety of therapeutic targets of the fluvoxamine, including antidepressant, anti-anxiety, cognitive effects, is certainly a significant advantage of the studied fluvoxamine for use in childhood.

Details

Language :
Russian
ISSN :
1997-7298
Volume :
123
Issue :
11. Vyp. 2
Database :
MEDLINE
Journal :
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Publication Type :
Academic Journal
Accession number :
38127696
Full Text :
https://doi.org/10.17116/jnevro202312311214